The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | The potential of caplacizumab in the treatment of aTTP
Eleni Gavriilaki, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, speaks on the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). In a real-world multicenter study, patients treated with caplacizumab had more favorable outcomes compared to historic controls. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Pfizer and Jazz Pharmaceuticals
Honoraria: Alexion, AstraZeneca, Omeros, Sanofi, Sobi
